{"protocolSection":{"identificationModule":{"nctId":"NCT03746301","orgStudyIdInfo":{"id":"20286"},"organization":{"fullName":"Bayer","class":"INDUSTRY"},"briefTitle":"Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation","officialTitle":"Xarelto® on Prevention of Stroke and Non-Central Nervous Systemic (CNS) Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation (NVAF)","acronym":"XARENAL"},"statusModule":{"statusVerifiedDate":"2022-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-12-03","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-07-28","type":"ACTUAL"},"completionDateStruct":{"date":"2021-12-15","type":"ACTUAL"},"studyFirstSubmitDate":"2018-11-16","studyFirstSubmitQcDate":"2018-11-16","studyFirstPostDateStruct":{"date":"2018-11-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-12-06","lastUpdatePostDateStruct":{"date":"2022-12-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bayer","class":"INDUSTRY"},"collaborators":[{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the study is to evaluate the safety and effectiveness of Xarelto in renally impaired patients with NVAF under routine practice conditions. The information collected in the XARENAL study will help to understand how renally impared patients with NVAF are treated in the real-world setting and what the outcome for the patients is under those conditions."},"conditionsModule":{"conditions":["Non-valvular Atrial Fibrillation (NVAF)"],"keywords":["Non-valvular Atrial fibrillation (NVAF), Stroke; Non-Central Nervous Systemic (CNS) embolism"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":924,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Treatment","description":"Patients will be followed according to routine medical practice and the frequency of visits and procedures will be performed under routine conditions.","interventionNames":["Drug: Rivaroxaban(Xarelto,BAY 59-7939)"]}],"interventions":[{"type":"DRUG","name":"Rivaroxaban(Xarelto,BAY 59-7939)","description":"10mg, 15mg and 20 mg film-coated tablets","armGroupLabels":["Treatment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence proportion of major bleeding","description":"Incidence proportion of major bleeding events collects as serious or non-serious AEs and defined as overt bleeding associated with:\n\n* a fall in haemoglobin of ≥2 g/dL, or\n* a transfusion of ≥2 units of packed red blood cells or whole blood, or\n* occurrence at a critical site (intracranial, intra-spinal, intraocular, pericardial, intra articular, intra muscular with compartment syndrome, retroperitoneal), or\n* death.","timeFrame":"Up to 12 months"}],"secondaryOutcomes":[{"measure":"Occurrence of AEs and SAEs","timeFrame":"Up to 12 months"},{"measure":"Occurrence of all-cause mortality","timeFrame":"Up to 12 months"},{"measure":"Occurrence of Non-major bleeding","description":"Non-major bleeding events collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleeding.","timeFrame":"Up to 12 months"},{"measure":"Incidence proportion of Symptomatic thromboembolic events","description":"Symptomatic thromboembolic events collected as SAEs or non-serious AEs.","timeFrame":"Up to 12 months"},{"measure":"Days of rivaroxaban treatment","description":"Start of rivaroxaban therapy and, if applicable, stop of rivaroxaban therapy(in case of treatment discontinuation, switch, or interruption, the reason will be recorded)","timeFrame":"Up to 12 months"},{"measure":"The change in creatinine clearance from baseline","timeFrame":"At month 3,6,9 and 12"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female and male patients ≥ 19 years of age\n* Diagnosis of NVAF\n* Patients for whom the decision to initiate treatment with rivaroxaban has already been made as per physician's routine treatment practice\n* Previous documented creatinine clearance rate of 15-49mL/min within 6 months before enrollment\n* Written informed consent of the patient\n\nExclusion Criteria:\n\n* Contraindications for rivaroxaban according to the current Korean market authorization and Summary of Product Characteristics (SmPC).\n* Patients participating in an investigational program with interventions outside of routine clinical practice.\n* Planned treatment with other anticoagulants.\n* Expected renal-replacement therapy within the next 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with NVAF who have moderate (creatinine clearance 30 - 49 ml/min) or severe (creatinine clearance 15 - 29 ml/min) renal impairment, requiring rivaroxaban for the prevention of stroke or non-CNS systemic embolism. Patients must also meet all the eligibility criteria for the study.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Many locations","city":"Multiple Locations","country":"Korea, Republic of"}]},"referencesModule":{"seeAlsoLinks":[{"label":"Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.","url":"http://clinicaltrials.bayer.com/"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA \"Principles for responsible clinical trial data sharing\". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.\n\nInterested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000001281","term":"Atrial Fibrillation"},{"id":"D000004617","term":"Embolism"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001145","term":"Arrhythmias, Cardiac"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M4276","name":"Atrial Fibrillation","asFound":"Atrial Fibrillation","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4143","name":"Arrhythmias, Cardiac","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}